Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Prices IPO at $4 a Share

Premium

Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.

The company said it has also granted the underwriters of the offering the option to buy an additional 1.7 million shares at the $4 offering price. If exercised, the option would boost the value of the IPO to $51.75 million.

The company anticipates going public this week under the symbol “RGLS.”

Previously, Regulus had said in a filing with the US Securities and Exchange Commission that it was considering floating 4.5 million shares at between $10 and $12 apiece (GSN 9/13/2012).